Loading…
← CockpitCompetitor Analysis › 8129.T Toho Holdings Co., Ltd.Open in the cockpit ↗

Toho Holdings Co., Ltd.8129.TCompetitor analysis, valuation and peers

Japan · JPY·Health Care›Medical Distributors

Japanese pharmaceutical wholesaler distributing drugs and medical devices to hospitals and pharmacies nationwide.

≈ A mid-size Japanese pharmaceutical distributor, like a smaller CencoraMomentum neutral 58
Mkt cap
$1.64B
US dollars, full cap
Free float
72%
of shares outstanding
$/day
$3.45M
20-day average traded
Fwd P/E
22.2×
forward earnings
ROIC−WACC
+0.8 pp
WACC 5.0%
Hurdle
-10 pp
Req g minus delivered
Next earnings
85 days
11 Feb 2027
Close · JPY¥3,959
1D-0.5%
1W+4.0%
1M-1.4%
3M+3.6%
6M-4.9%
YTD-15.2%
1Y-16.4%
ATR %2.6%
52w lowhigh21.3% off high

What Toho does

Japanese pharmaceutical wholesaler distributing drugs and medical devices to hospitals and pharmacies nationwide.

Buys drugs from makers and delivers them to hospitals and pharmacies, earning a thin margin that is squeezed when the government revises official drug prices, so volume, delivery efficiency and negotiating power matter.

In one line: A mid-size Japanese pharmaceutical distributor, like a smaller Cencora.

Products and services

  • Pharmaceutical wholesale distribution
  • Medical device distribution

Customers

  • Hospitals
  • Pharmacies
  • Clinics

Where it sits in the supply chain

  • Health care
  • Pharmaceutical distribution
  • Wholesale distribution of drugs and…

What could go right

  • Drug volume growth from aging population

What could go wrong

  • Thin distribution margins
  • Drug price revisions by government

Moat: narrow (scale, distribution, regulatory licence). Nationwide licensed distribution network and scale purchasing in a low-margin, logistics-heavy business.

Headquarters: Tokyo, Japan · Founded: 1932 · Employees: 7,675

Named competitors

Toho at a glance

Size Toho (8129.T) is a Japan Health Care company (Medical Distributors) with a market value of $1.64B, the 544th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥3,959 on 18 Nov 2026.

Performance Over six months the shares fell 4.9%, against +7.6% for the median peer and -1.4% for the Japan market (cap-weighted) — 6th lowest of 21 in its peer set.

Growth Revenue grew 4.1% over the last twelve months (peer median +6.3%); the operating margin is 0.9% (peer median 3.2%).

Valuation It trades at 22.2× forward earnings against a peer median of 15.8× (3rd most expensive of 16).

Price implies For today's price to make sense, revenue must grow about -5% a year for seven years (Req g). Recent delivered growth is +5%, so the hurdle is -10 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 0.8 points above its cost of capital (5.0% WACC).

Next results Next results expected around 11 Feb 2027 (exchange calendar; dates can move).

Relative performance

9010011021 May 202621 Aug 202618 Nov 2026Peer median 1088129.T 94
Six months, rebased to 100: Toho against the median of its 20 peers (local-currency closes).

Toho financials

Reported figures in JPY; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue¥1.59T¥1.55T¥1.52T¥1.48T¥1.39T
Revenue growth—+2%+3%+6%—
Gross profit¥116B¥117B¥116B¥113B¥105B
EBITDA¥20.6B¥22.5B¥24.9B¥25.7B¥19.2B
Net income¥15.3B¥17.3B¥19.8B¥20.7B¥13.6B
Free cash flown/a¥13.0B-¥30.7B¥57.4B-¥1.65B
Capital expendituren/a¥9.51B¥5.76B¥3.78B¥2.52B
Total debt¥5.56B¥9.89B¥21.3B¥30.2B¥37.9B

Quarterly statements and history in the cockpit →

Toho competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%+40%+60%0%+20%RDC336099876005877476DOCM301584008930600713ASKERARJO-B2784ENTERO68263349AMP6009988129.T6-month return →1-month return →
Up and to the right = strong over both horizons. Toho is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%+30%20×40×336099876005877476ASKER603368ARJO-B2784ENTERO6826AMP8129.TRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Toho is the large dot.

Capital: growth delivered against growth the price implies

0%+20%0%20%336099876005877476301584008930ASKERARJO-BENTERO6826NEU8129.TGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Toho is the large dot.

Toho competitors and peer comparison

Head to head with its named competitors (8129.T vs 7459.T vs 2784.T vs 9987.T)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Toho 8129.T$1.64B-5%+4%1%22.2×-4.6%
MEDIPAL 7459.T$3.70B+15%+4%1%12.5×-7.2%
Alfresa 2784.T$2.81B-3%+4%1%18.4×-8.4%
Suzuken 9987.T$2.36B+8%+5%1%15.8×-10.4%

How Toho compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Toho against its 20 peers (data as of 18 Nov 2026)
Measure8129.TPeer medianRank in peer set
1-month return-1.4%+1.5%6th lowest of 21
6-month return-4.9%+7.6%6th lowest of 21
Distance from 52-week high-21.3%-15.8%7th lowest of 21
Revenue growth (TTM)+4.1%+6.3%8th lowest of 21
Operating margin0.9%3.2%4th lowest of 21
Forward P/E22.2×15.8×3rd most expensive of 16
Growth the price implies (Req g, 7 yrs)-4.6%-0.5%7th least demanding of 17
Growth delivered (Del g)+5.1%+7.7%6th lowest of 17
Hurdle (Req g minus delivered)-9.7 pp-7.8 pp7th least demanding of 17
ROIC minus cost of capital+0.8 pp+1.7 pp10th lowest of 21
Net debt / EBITDA-4.7×1.2×least indebted of 14

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Toho 8129.TJapan$1.64B-5%+4%1%22.2×-4.6%+5.1%
Redcare Pharmacy RDC.DEGermany$1.50B+53%+19%0%n/an/an/a
Ship Healthcare 3360.TJapan$1.38B+19%+6%3%14.6×-14.5%+7.6%
Suzuken 9987.TJapan$2.36B+8%+5%1%15.8×-10.4%+3.2%
Shinva Medical Instrument 600587.SSChina$1.10B-10%+6%5%13.4×-6.9%+1.2%
AS ONE 7476.TJapan$1.10B+25%+10%12%18.4×0.0%+6.3%
DocMorris DOCM.SWSwitzerland$1.08B+169%+11%-8%n/an/an/a
Shanghai C and D INNOSTIC Medical Technology 301584.SZChina$1.06B-33%+8%3%n/a-2.7%+17.9%
Hanmi Science 008930.KSSouth Korea$2.58B+48%+6%4%n/a26.0%+9.6%
Nanjing Pharmaceutical 600713.SSChina$999M-2%+3%2%n/an/an/a
Asker Healthcare ASKER.STSweden$2.69B-14%+12%7%24.8×4.7%+12.7%
Guangxi LiuYao 603368.SSChina$975M+1%+2%5%9.5×-9.7%+6.0%
Arjo ARJO-B.STSweden$974M+42%0%8%21.1×-1.0%+3.9%
Alfresa 2784.TJapan$2.81B-3%+4%1%18.4×-8.4%+3.5%
Entero Healthcare Solutions ENTERO.NSIndia$925M+60%+35%4%47.7×24.7%+29.9%
Shanghai Haohai Biological Technology 6826.HKHong Kong$897M-24%-5%-2%7.7×17.0%+12.4%
COSMOS Pharmaceutical 3349.TJapan$3.21B+2%+9%4%15.9×n/an/a
Neuca NEU.WAPoland$795M-9%+8%2%15.3×5.3%+8.1%
Amplifon AMP.MIItaly$3.39B+8%0%10%17.0×6.8%+9.8%
MEDIPAL 7459.TJapan$3.70B+15%+4%1%12.5×-7.2%+3.5%
Jointown Pharmaceutical 600998.SSChina$3.99B+7%+9%2%11.8×0.2%+7.8%

Questions

Who are Toho's main competitors?
Named competitors: Medipal Holdings (7459.T), Alfresa Holdings (2784.T), Suzuken (9987.T). The cockpit's measured peer set (industry) also includes Redcare Pharmacy (RDC.DE), Ship Healthcare (3360.T), Suzuken (9987.T), Shinva Medical Instrument (600587.SS), AS ONE (7476.T), DocMorris (DOCM.SW).
Is Toho expensive compared with its peers?
On forward p/e it trades at 22.2× against a peer median of 15.8×, 3rd most expensive of 16 in its peer set. For today's price to make sense, revenue must grow about -5% a year for seven years (Req g). Recent delivered growth is +5%, so the hurdle is -10 pp: the price already allows for a slowdown.
How has Toho stock performed?
Over six months to 18 Nov 2026 the shares returned -4.9% against +7.6% for the median peer; over one year -16.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.